Journal of Mid-Life Health (Jan 2022)

Leydig cell hyperplasia of ovary – An unusual finding in postneoadjuvant chemotherapy case of primary fallopian tube carcinoma

  • Kriti Chaturvedi,
  • Meenakshi Rao,
  • Souvik Saha,
  • Jeewan Ram Vishnoi,
  • Aasma Nalwa

DOI
https://doi.org/10.4103/jmh.jmh_117_22
Journal volume & issue
Vol. 13, no. 3
pp. 247 – 250

Abstract

Read online

A large number of high-grade serous ovarian carcinomas originate in the fallopian tubes. Neoadjuvant chemotherapy followed by surgery may lead to a number of chemotherapy-induced changes in the ovary, which may lead to an erroneous diagnosis. We present a rare case of a 55-year-old postmenopausal woman who was clinically diagnosed with carcinoma of the right ovary; on histopathologic evaluation after neoadjuvant chemotherapy, the primary site was found to be the right fallopian tube. The right ovary showed chemotherapy-related changes along with extensive Leydig cell hyperplasia. As the presence of Leydig cell hyperplasia in this setting is an unusual finding, it may pose a diagnostic dilemma for the pathologist; so an awareness of this entity is important to avoid misdiagnosis.

Keywords